Since the circadian feature of PER2 expression in peripheral blood of tumor‐bearing mice is consistent with that in OSCC tissue (Figure S1a–c, Supporting Information), it is feasible to utilize PER2 in peripheral blood as a biomarker to guide chronomodulated drug delivery of DNA‐damaging agents. The gene discussed is PER2; the disease is neoplasm.